Silodosin in Retrograde Intrarenal Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 4, 2023

Primary Completion Date

July 1, 2023

Study Completion Date

September 1, 2023

Conditions
Urolithiasis
Interventions
DRUG

Silodosin 8 mg

"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~silodosin is an alpha blocker which act to dilate the ureter to facilitate access sheath placement"

DRUG

Placebo

"This prospective study will be conducted on patients prepared for Retrograde intrarenal surgery presented to Ain Shams University Hospital. Patients will be randomized with 1:1 ratio into 2 equal groups.~Group A (the study group): Patients will receive silodosin 8 mg one tablet per day for 7 days before their scheduled retrograde intrarenal surgery.~Group B (the control group): Patients will receive Placebo for 7 days before their scheduled retrograde intrarenal surgery."

Trial Locations (1)

11757

Ahmed Maher, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05921370 - Silodosin in Retrograde Intrarenal Surgery | Biotech Hunter | Biotech Hunter